Safety Study to Assess the Feasibility of Use in Humans of the TAXUS Petal Bifurcation Coronary Stent System

Inclusion Criteria - Phases 1 and 2 * Age is ≥18 years old and ≤80 years old * Eligible for PCI * Acceptable candidate for CABG * Documented stable angina pectoris (CCS Classification 1, 2, 3, or 4) or unstable angina pectoris with documented ischemia (Braunwald Class IB-C, IIB-C, or IIIB-C), or documented silent ischemia * LVEF known to be ≥40% * Clinical angiographic success in non-target lesion (if a non-target lesion is treated) * Subject (or legal guardian) understands the study requirements and procedures and provides written Informed Consent before any study tests or procedures are performed * Subject willing to comply with follow-up evaluations Exclusion Criteria - Phases 1 and 2 * Contraindication to ASA, or to Thienopyridine derivatives (e.g. Clopidogrel, Ticlopidine) * High risk of bleeding * Known hypersensitivity to paclitaxel * Known allergy to stainless steel * Known allergy to platinum * Previous treatment of the target vessel with any anti-restenotic drug-coated or drug-eluting coronary stent * Previous treatment of the target vessel with BMS within 9 months before index procedure * Previous treatment of any non-target vessel with any anti-restenotic drug-coated or DES within 9 months before index procedure * Previous treatment with intravascular brachytherapy in the target vessel * Planned PCI or CABG post-index procedure * Planned target vessel treatment with an unapproved device, directional or rotational coronary atherectomy, laser, cutting balloon, or transluminal extraction catheter * Documented MI within 72 hours prior to index procedure * CK \> 2 x ULN + positive CK-MB OR * CK \> 2 x ULN + positive troponin OR * If no CK-MB or troponin was drawn, patients are excluded with CK \> 2xULN * As per protocol definitions found in Appendix A: * CVA within the past 6 months * Cardiogenic shock * Acute or chronic renal dysfunction * Prior anaphylactic reaction to contrast agents * Leukopenia * Thrombocytopenia * Thrombocytosis * Active peptic ulcer or active GI bleeding * Current treatment, or past-treatment within 12 months of the index procedure, with paclitaxel or other chemotherapeutic agents * Anticipated treatment with paclitaxel or oral rapamycin within 9 months of index procedure * Subject's (men and women) known intention to procreate within 9 months of index procedure * Positive pregnancy test or nursing an infant within 7 days prior to index procedure * Life expectancy of less than 24 months due to other medical conditions * Co-morbid condition(s) that could limit subject's ability to comply with study follow-up or impact study scientific integrity * Currently participating in another investigational drug or device clinical study * Planned surgery at time of enrollment within the next 9 months after index procedure Angiographic Inclusion Criteria - Phases 1 \& 2 * Target Lesion (main and / or side branch): * located in native coronary artery * must be de novo * main branch %DS is ≥50% and \<100% * is a bifurcation lesion with an angle ≥30º and ≤90º * is enrolled after successful pre-dilatation of the target vessel Angiographic Inclusion Criteria - Phase 1 * Main branch of target lesion located in parent branch of LAD or LCx or RCA * Target lesion located in proximal or mid-section of vessel only (crux of RCA \[distal RCA\] is allowed) * Main branch RVD ≥3.00 mm to ≤3.5 mm; lesion length ≤20 mm (to be covered by TAXUS® Petal™ stent and maximum of 1 additional TAXUS stent ≤12 mm in length) * Side branch RVD ≥2.5 mm to ≤3.5 mm; lesion length ≤14 mm to be treated by maximum of 1 TAXUS stent ≤16 mm in length Angiographic Inclusion Criteria - Phase 2 * Main branch of target lesion located in parent branch of LAD or LCx or RCA without restrictions * Main branch RVD ≥3.00 mm to ≤3.5 mm; lesion length ≤28 mm (to be covered by TAXUS® Petal™ stent and maximum of 1 additional TAXUS stent ≤20 mm in length) * Side branch RVD ≥2.25 mm to ≤3.5 mm; lesion length ≤14 mm to be treated by maximum of 1 TAXUS stent ≤16 mm in length Angiographic Exclusion Criteria - Phases 1 \& 2 * Target lesion located in left main (protected or unprotected) * Medina Classification 0.0.1 * Target lesion is restenotic * Target lesion located in a SVG or mammary artery graft * Target lesion accessed via SVG or mammary artery graft * Target lesion is \<5 mm from BMS * Target lesion is \<5 mm from second side branch vessel ≥1.5 mm in diameter * Untreated lesions with ≥50% DS or thought to impair flow remaining in target vessel * Target lesion and/or vessel proximal to target lesion moderately or severely calcified * Target lesion and/or target vessel proximal to target lesion severely tortuous * Main branch target lesion located within or distal to a \>60° bend in target vessel * Target vessel with angiographic presence of probable or definite thrombus * Unprotected LM disease * Protected LM disease with target lesion in LAD or LCx (subject may be enrolled if only lesion is target lesion in RCA) Angiographic Exclusion Criteria * Phase 1: Target lesion TIMI flow \<3 * Phase 2: Target lesion TIMI flow \<2